FTCCI Excellence Award – Presented to Maithri Drugs Private Limited, Hyderabad. In recognition of EXCELLENCE IN RESEARCH & DEVELOPMENT Instituted by Spectra Shares & Scrips P. Ltd., Hyderabad

Maithri Drugs Private Limited, Hyderabad is one of India’s fast-growing pharmaceutical
companies. Maithri’s strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies.
It is a R&D-driven company, committed to excellence, innovation, and quality to make the world a healthier place to live. The R&D strategy has helped them to develop breakthrough technologies that led to increased process efficiency, cost-competitive chemistry, and accurate analysis, meeting stringent regulatory requirements. R&D scientists are always enthusiastic about developing niche generic molecules that address potential demand across global markets.
It has developed Selexipag, one of the molecules for which there was a growing need to improve
the existing innovator process. The R&D team was successful, improving the development process and efficacy of the molecule to treat PAH (Pulmonary Arterial Hypertension). The product is used for adults to treat Pulmonary Arterial Hypertension (PAH – high blood pressure in the vessels that carry blood to the lungs) to slow down the worsening of symptoms and reduce the chance of being hospitalized for PAH.
The development process for this product is protected in 4 countries (USA, Canada, Europe, and
India).
In recognition of their excellent achievements in research & development, the FTCCI Excellence
Award for ‘Excellence in Research & Development is awarded to Maithri Drugs Private Limited,
Hyderabad.
Source: nagarjun@maithridrugs.com